Drug Profile
Lipid encapsulated oxaliplatin - LiPlasome Pharma
Alternative Names: LiPloxaLatest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator LiPlasome Pharma
- Class Antineoplastics; Platinum complexes; Small molecules
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Cancer in Denmark (IV)
- 13 Jul 2020 Lipid encapsulated oxaliplatin is still in preclinical development for Cancer in Denmark (IV) (LiPlasome Pharma pipeline, July 2020)
- 25 Feb 2011 Preclinical trials in Cancer in Denmark (IV)